X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Regeneron will strengthen its gene therapy and heraing loss programs by gaining Decibel's lead candidate, DB-OTO, which is currently in Phase 1/2 and is an investigational cell-selective, AAV gene therapy to treat congenital, monogenic hearing loss.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $213.0 million Upfront Cash: $213.0 million
Deal Type: Acquisition September 25, 2023
Details:
Through the acquisition, Regeneron will strengthen its gene therapy and heraing loss programs by gaining Decibel's lead candidate, DB-OTO, which is currently in Phase 1/2 and is an investigational cell-selective, AAV gene therapy to treat congenital, monogenic hearing loss.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $213.0 million Upfront Cash: $213.0 million
Deal Type: Acquisition August 09, 2023
Details:
DB-OTO is a gene therapy product candidate designed to provide durable restoration (selectively express functional OTOF in the inner hair cells) of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2023
Details:
DB-OTO is a gene therapy product candidate designed to provide durable restoration (selectively express functional OTOF in the inner hair cells) of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
DB-OTO is a gene therapy product candidate designed to provide durable restoration (selectively express functional OTOF in the inner hair cells) of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
DB-OTO uses a proprietary, cell-selective promoter to express the otoferlin transgene in hair cells, with the goal of enabling the ear to transmit sound to the brain and provide hearing.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals and is an adeno-associated virus (AAV)-based dual-vector gene therapy designed to provide durable hearing to individuals with profound congenital hearing loss caused by mutations of the otoferlin gene.
Lead Product(s): Otoferlin
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020, a novel, proprietary formulation of sodium thiosulfate treated ear.
Lead Product(s): Sodium Thiosulfate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-020
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
DB-OTO is a gene therapy product candidate designed to provide durable restoration of hearing to individuals born with profound hearing loss due to mutation of the OTOF gene.
Lead Product(s): DB-OTO
Therapeutic Area: Genetic Disease Product Name: DB-OTO
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Podium presentation at ARO annual midwinter meeting highlighting DB-OTO, gene therapy cell-selective promoter to control otoferlin transgene expression in hair cells, dose-ranging studies with expression analysis, functional recovery, and tolerability data.
Lead Product(s): DB-OTO
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: DB-OTO
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
